CERNER (CERN) 10-Q 29 Oct 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Oct. 21, 2020
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	0-15386
Entity Registrant Name	CERNER CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2800 Rockcreek Parkway
Entity Address, City or Town	North Kansas City,
Entity Address, State or Province	MO
Entity Tax Identification Number	43-1196944
Entity Address, Postal Zip Code	64117
City Area Code	816
Local Phone Number	221-1024
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	CERN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		306,589,898
Entity Central Index Key	0000804753
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 28, 2019
Current assets:
Cash and cash equivalents	$ 419,154	$ 441,843
Short-term investments	473,323	99,931
Receivables, net	1,219,227	1,139,595
Inventory	15,768	23,182
Prepaid expenses and other	397,487	392,073
Total current assets	2,524,959	2,096,624
Property and equipment, net	1,867,600	1,858,772
Right-of-use assets	109,659	123,155
Software development costs, net	991,649	939,859
Goodwill	907,105	883,158
Intangible assets, net	330,837	364,439
Long-term investments	423,315	419,419
Other assets	205,688	209,196
Total assets	7,360,812	6,894,622
Current liabilities:
Accounts payable	256,449	273,440
Deferred revenue	320,294	360,025
Accrued payroll and tax withholdings	328,663	245,843
Other current liabilities	196,170	148,140
Total current liabilities	1,101,576	1,027,448
Long-term Debt	1,336,018	1,038,382
Deferred income taxes	391,790	377,657
Other liabilities	125,141	133,807
Total liabilities	2,954,525	2,577,294
Shareholders' Equity:
Common stock, $0.01 par value, 500,000,000 shares authorized, 372,272,953 shares issued at September 30, 2020 and 367,634,796 shares issued at December 28, 2019	3,723	3,676
Additional paid-in capital	2,196,127	1,905,171
Retained earnings	6,402,220	5,934,909
Treasury stock, 65,919,144 shares at September 30, 2020 and 56,723,546 shares at December 28, 2019	(4,057,768)	(3,407,768)
Accumulated other comprehensive loss, net	(138,015)	(118,660)
Total shareholders' equity	4,406,287	4,317,328
Total liabilities and shareholders' equity	$ 7,360,812	$ 6,894,622
Common stock, par value	$ 0.01
Common Stock, Shares Authorized	500,000,000
Common stock, shares issued	372,272,953	367,634,796
Treasury Stock, Shares	65,919,144	56,723,546

Consolidated Statements Of Oper

Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019	Sep. 30, 2020	Sep. 28, 2019
Revenues	$ 1,368,673	$ 1,429,428	$ 4,110,763	$ 4,250,366
Costs and expenses:
Costs of revenue	231,889	271,778	698,268	793,655
Sales and client service	625,402	707,743	1,907,138	2,026,825
Software development (Includes amortization of $61,578 and $183,786 for the three and nine months ended September 30, 2020, respectively; and $56,786 and $169,036 for the three and nine months ended September 28, 2019, respectively)	186,826	187,526	551,101	548,934
General and administrative	116,816	152,321	391,000	398,305
Amortization of acquisition-related intangibles	12,789	21,283	43,031	64,809
Total costs and expenses	1,173,722	1,340,651	3,590,538	3,832,528
Gain on sale of businesses	216,869	0	216,869	0
Operating earnings	411,820	88,777	737,094	417,838
Other income, net	48,020	13,535	78,247	44,973
Earnings before income taxes	459,840	102,312	815,341	462,811
Income taxes	(103,164)	(20,377)	(176,758)	(87,688)
Net earnings	$ 356,676	$ 81,935	$ 638,583	$ 375,123
Basic earnings per share	$ 1.17	$ 0.26	$ 2.08	$ 1.17
Diluted earnings per share	$ 1.16	$ 0.26	$ 2.07	$ 1.16
Basic weighted average shares outstanding	305,759	315,876	306,759	320,282
Diluted weighted average shares outstanding	308,366	319,113	309,124	323,361
Software development, amortization	$ 61,578	$ 56,786	$ 183,786	$ 169,036

Consolidated Statements Of Comp

Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019	Sep. 30, 2020	Sep. 28, 2019
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Net earnings	$ 356,676	$ 81,935	$ 638,583	$ 375,123
Foreign currency translation adjustment and other (net of taxes (benefit) of $351 and $688 for the three and nine months ended September 30, 2020; and $(409) and $(413) for the three and nine months ended September 28, 2019, respectively)	9,611	(11,679)	(1,738)	(9,458)
Unrealized gain (loss) on cash flow hedge (net of taxes (benefit) of $745 and $(5,937) for the three and nine months ended September 30, 2020; and $(1,327) and $(5,396) for the three and nine months ended September 28, 2019, respectively)	2,265	(4,037)	(18,050)	(16,407)
Unrealized holding gain (loss) on available-for-sale investments (net of taxes (benefit) of $(73) and $142 for the three and nine months ended September 30, 2020; and $5 and $286 for the three and nine months ended September 28, 2019, respectively)	(220)	14	433	867
Comprehensive income	368,332	66,233	619,228	350,125
Foreign currency translation adjustment and other, taxes (benefit)	351	(409)	688	(413)
Unrealized loss on cash flow hedge, (taxes) benefit	(745)	1,327	5,937	5,396
Change in net unrealized holding gain (loss) on available-for-sale investments, taxes (benefit)	$ (73)	$ 5	$ 142	$ 286

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings	$ 638,583	$ 375,123
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	518,987	509,559
Share-based compensation expense	110,500	73,421
Provision for deferred income taxes	21,554	22,793
Gain on sale of businesses	(216,869)	0
Investment gains	(75,834)	(24,231)
Changes in assets and liabilities:
Receivables, net	(78,695)	24,558
Inventory	8,206	1,877
Prepaid expenses and other	(36,664)	(75,191)
Accounts payable	(60,808)	(3,346)
Accrued income taxes	33,005	(795)
Deferred revenue	(32,071)	(89,400)
Other accrued liabilities	94,151	61,156
Net cash provided by operating activities	924,045	875,524
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital purchases	(238,053)	(388,588)
Capitalized software development costs	(224,710)	(211,284)
Purchases of investments	(511,378)	(317,979)
Sales and maturities of investments	213,309	507,258
Purchase of other intangibles	(29,698)	(25,794)
Sale of businesses	229,471	0
Acquisition of businesses, net of cash acquired	(35,766)	0
Net cash used in investing activities	(596,825)	(436,387)
CASH FLOWS FROM FINANCING ACTIVITIES:
Long-term debt issuance	300,000	600,000
Repayments of Long-term Debt	(2,500)	0
Proceeds from exercise of stock options	202,680	188,474
Payments to taxing authorities in connection with shares directly withheld from associates	(22,623)	(14,994)
Treasury stock purchases	(650,000)	(1,020,542)
Dividends paid	(166,277)	(57,293)
Other financing activities	(6,807)	(8,450)
Net cash provided by (used in) financing activities	(345,527)	(312,805)
Effect of exchange rate changes on cash and cash equivalents	(4,382)	(4,028)
Net increase (decrease) in cash and cash equivalents	(22,689)	122,304
Cash and cash equivalents at beginning of period	441,843	374,126
Cash and cash equivalents at end of period	$ 419,154	$ 496,430

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjustment	Treasury Stock [Member]	AOCI Attributable to Parent [Member]
Balance at Dec. 29, 2018		$ 3,622	$ 1,559,562	$ 5,576,525		$ (2,107,768)	$ (103,552)
Common stock, shares issued at Dec. 29, 2018		362,213,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		$ 7	11,716
Exercise of stock options, shares		706,000
Employee share-based compensation expense			19,860
Other Comprehensive Income (Loss)							2,958
Net earnings				166,219
Balance at Mar. 30, 2019		$ 3,629	1,591,138	5,742,744		(2,107,768)	(100,594)
Common Stock, shares issued at Mar. 30, 2019		362,919,000
Balance at Dec. 29, 2018		$ 3,622	1,559,562	5,576,525		(2,107,768)	(103,552)
Common stock, shares issued at Dec. 29, 2018		362,213,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	$ 375,123
Balance at Sep. 28, 2019		$ 3,662	1,806,939	5,836,984		(3,107,768)	(128,550)
Common Stock, shares issued at Sep. 28, 2019		366,201,000
Balance at Mar. 30, 2019		$ 3,629	1,591,138	5,742,744		(2,107,768)	(100,594)
Common stock, shares issued at Mar. 30, 2019		362,919,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		$ 18	108,045
Exercise of stock options, shares		1,777,000
Employee share-based compensation expense			23,024
Other Comprehensive Income (Loss)							(12,254)
Treasury stock purchases						(600,000)
Cash dividends declared ($0.18 per share)				(57,682)
Net earnings				126,969
Balance at Jun. 29, 2019		$ 3,647	1,722,207	5,812,031		(2,707,768)	(112,848)
Common Stock, shares issued at Jun. 29, 2019		364,696,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		$ 15	54,195
Exercise of stock options, shares		1,505,000
Employee share-based compensation expense			30,537
Other Comprehensive Income (Loss)							(15,702)
Treasury stock purchases						(400,000)
Cash dividends declared ($0.18 per share)				(56,982)
Net earnings	81,935			81,935
Balance at Sep. 28, 2019		$ 3,662	1,806,939	5,836,984		(3,107,768)	(128,550)
Common Stock, shares issued at Sep. 28, 2019		366,201,000
Balance at Dec. 28, 2019	$ 4,317,328	$ 3,676	1,905,171	5,934,909	$ (4,606)	(3,407,768)	(118,660)
Common stock, shares issued at Dec. 28, 2019	367,634,796	367,635,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		$ 26	114,050
Exercise of stock options, shares		2,543,000
Employee share-based compensation expense			35,031
Other Comprehensive Income (Loss)							(40,703)
Treasury stock purchases						(650,000)
Cash dividends declared ($0.18 per share)				(55,206)
Net earnings				147,159
Balance at Mar. 31, 2020		$ 3,702	2,054,252	6,022,256		(4,057,768)	(159,363)
Common Stock, shares issued at Mar. 31, 2020		370,178,000
Balance at Dec. 28, 2019	$ 4,317,328	$ 3,676	1,905,171	5,934,909	$ (4,606)	(3,407,768)	(118,660)
Common stock, shares issued at Dec. 28, 2019	367,634,796	367,635,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock purchases	$ 650,000
Net earnings	638,583
Balance at Sep. 30, 2020	$ 4,406,287	$ 3,723	2,196,127	6,402,220		(4,057,768)	(138,015)
Common Stock, shares issued at Sep. 30, 2020	372,272,953	372,273,000
Balance at Mar. 31, 2020		$ 3,702	2,054,252	6,022,256		(4,057,768)	(159,363)
Common stock, shares issued at Mar. 31, 2020		370,178,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		$ 10	28,540
Exercise of stock options, shares		1,009,000
Employee share-based compensation expense			37,549
Other Comprehensive Income (Loss)							9,692
Cash dividends declared ($0.18 per share)				(55,602)
Net earnings				134,748
Balance at Jun. 30, 2020		$ 3,712	2,120,341	6,101,402		(4,057,768)	(149,671)
Common Stock, shares issued at Jun. 30, 2020		371,187,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		$ 11	37,866
Exercise of stock options, shares		1,086,000
Employee share-based compensation expense			37,920
Other Comprehensive Income (Loss)							11,656
Cash dividends declared ($0.18 per share)				(55,858)
Net earnings	$ 356,676			356,676
Balance at Sep. 30, 2020	$ 4,406,287	$ 3,723	$ 2,196,127	$ 6,402,220		$ (4,057,768)	$ (138,015)
Common Stock, shares issued at Sep. 30, 2020	372,272,953	372,273,000

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Supplemental Disclosures of Cash Flow Information Nine Months Ended (In thousands) 2020 2019 Cash paid during the period for: Interest (including amounts capitalized of $12,040 and $12,575, respectively) $ 31,661 $ 20,756 Income taxes, net of refunds 78,519 65,171 Non-cash items: Lease liabilities recorded upon the commencement of operating leases 24,499 23,129 Capital purchases 17,395 7,600

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information details - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019
Supplemental Cash Flow Elements [Abstract]
Interest Paid, Capitalized	$ 12,040	$ 12,575
Interest Paid	31,661	20,756
Income Taxes Paid, Net	78,519	65,171
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	24,499	23,129
Capital Expenditures Incurred but Not yet Paid	$ 17,395	$ 7,600

Interim Statement Presentation

Interim Statement Presentation (Notes)	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interim Statement Presentation	Interim Statement Presentation Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Cerner Corporation ("Cerner," the "Company," "we," "us" or "our") without audit, pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our latest annual report on Form 10-K. In management's opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position and the results of operations and cash flows for the periods presented. Our interim results as presented in this Form 10-Q are not necessarily indicative of the operating results for the entire year. The condensed consolidated financial statements were prepared using GAAP. These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Fiscal Period End Prior to fiscal year 2020, our third fiscal quarter ended on the Saturday closest to September 30. The third quarter and year-to-date periods for 2019 presented herein consisted of 91 days and 273 days, respectively, and ended on September 28, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, the third quarter and year-to-date periods for 2020 presented herein consisted of 92 days and 277 days, respectively, and ended on September 30, 2020. All references to periods in these notes to condensed consolidated financial statements represent the respective periods described above ending on September 30, 2020 and September 28, 2019, unless otherwise noted. Supplemental Disclosures of Cash Flow Information Nine Months Ended (In thousands) 2020 2019 Cash paid during the period for: Interest (including amounts capitalized of $12,040 and $12,575, respectively) $ 31,661 $ 20,756 Income taxes, net of refunds 78,519 65,171 Non-cash items: Lease liabilities recorded upon the commencement of operating leases 24,499 23,129 Capital purchases 17,395 7,600 CARES Act Cash flows from operating activities for the first nine months of 2020 include the impact of $56 million of certain federal payroll taxes related to pay cycles in the second and third quarters of 2020, for which we have deferred remittance to the taxing authority as permitted under the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"). We expect to continue to defer the remittance of such payroll taxes for the remainder of 2020, as permitted by the CARES Act, for which the remittances to the taxing authority are to be paid in equal amounts at the end of 2021 and 2022, respectively. At September 30, 2020, these deferred remittances are included in "Accrued payroll and tax withholdings" in our condensed consolidated balance sheets. Accounting Pronouncements Adopted in 2020 Credit Losses on Financial Instruments. In the first quarter of 2020, we adopted new guidance regarding impairment assessment for certain financial assets. Refer to Notes (3) and (4) for further details. Collaborative Arrangements. In November 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 , which clarifies when transactions between participants in a collaborative arrangement are within the scope of the FASB's recent revenue standard (Topic 606). Such guidance clarifies revenue recognition and financial statement presentation for transactions between collaboration participants. We adopted ASU 2018-18 in the first quarter of 2020. Such guidance did not have an impact on our consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements Reference Rate Reform. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform, such as the upcoming discontinuance of the London Interbank Offered Rate ("LIBOR"). The accommodations within ASU 2020-04 may be applied prospectively from the beginning of our 2020 first quarter through December 31, 2022. We are currently evaluating the effect that ASU 2020-04 may have on our contracts that reference LIBOR, specifically, our Third Amended and Restated Credit Agreement (as amended, the "Credit Agreement") and related interest rate swap. As of the date of this filing, we have not elected to apply any of the provisions of this standard.

Revenue from Contracts with Cus

Revenue from Contracts with Customers (Notes)	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Revenue Recognition Disaggregation of Revenue The following tables present revenues disaggregated by our business models: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Licensed software $ 159,327 $ 12,367 $ 171,694 $ 144,599 $ 9,934 $ 154,533 Technology resale 45,217 1,896 47,113 65,103 5,072 70,175 Subscriptions 87,878 5,529 93,407 85,230 6,674 91,904 Professional services 433,127 46,768 479,895 446,562 60,893 507,455 Managed services 280,827 31,017 311,844 272,933 29,502 302,435 Support and maintenance 219,682 40,296 259,978 227,131 50,163 277,294 Reimbursed travel 4,711 31 4,742 23,705 1,927 25,632 Total revenues $ 1,230,769 $ 137,904 $ 1,368,673 $ 1,265,263 $ 164,165 $ 1,429,428 Nine Months Ended 2020 2019 (In thousands) Domestic Segment International Segment Total Domestic Segment International Segment Total Licensed software $ 444,774 $ 37,114 $ 481,888 $ 466,105 $ 40,018 $ 506,123 Technology resale 126,042 14,675 140,717 169,112 17,338 186,450 Subscriptions 260,095 19,749 279,844 246,505 19,460 265,965 Professional services 1,295,759 156,564 1,452,323 1,313,701 169,500 1,483,201 Managed services 836,242 92,114 928,356 818,818 85,661 904,479 Support and maintenance 663,399 144,296 807,695 679,214 151,454 830,668 Reimbursed travel 19,086 854 19,940 68,750 4,730 73,480 Total revenues $ 3,645,397 $ 465,366 $ 4,110,763 $ 3,762,205 $ 488,161 $ 4,250,366 The following tables present our revenues disaggregated by timing of revenue recognition: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Revenue recognized over time $ 1,143,515 $ 132,891 $ 1,276,406 $ 1,143,470 $ 155,017 $ 1,298,487 Revenue recognized at a point in time 87,254 5,013 92,267 121,793 9,148 130,941 Total revenues $ 1,230,769 $ 137,904 $ 1,368,673 $ 1,265,263 $ 164,165 $ 1,429,428 Nine Months Ended 2020 2019 (In thousands) Domestic Segment International Segment Total Domestic Segment International Segment Total Revenue recognized over time $ 3,410,827 $ 437,791 $ 3,848,618 $ 3,403,965 $ 445,320 $ 3,849,285 Revenue recognized at a point in time 234,570 27,575 262,145 358,240 42,841 401,081 Total revenues $ 3,645,397 $ 465,366 $ 4,110,763 $ 3,762,205 $ 488,161 $ 4,250,366 Transaction Price Allocated to Remaining Performance Obligations As of September 30, 2020, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $13.01 billion of which we expect to recognize approximately 30% of the revenue over the next 12 months and the remainder thereafter. Contract Liabilities Customer payments received in advance of satisfaction of the related performance obligations are deferred as contract liabilities. Such amounts are classified in our condensed consolidated balance sheets as "Deferred revenue". During the nine months ended September 30, 2020, we recognized $306 million of revenues that were included in our contract liability balance at the beginning of such period. Significant Customers A certain customer within our Domestic segment comprised 19% and 12% of our consolidated revenues for the third quarters of 2020 and 2019, respectively; and 17% and 11% for the first nine months of 2020 and 2019, respectively. Amounts due from this same customer comprised 14% of client receivables as of September 30, 2020.

Receivables

Receivables	9 Months Ended
	Sep. 30, 2020
Receivables [Abstract]
Receivables	Receivables A summary of net receivables is as follows: (In thousands) September 30, 2020 December 28, 2019 Client receivables $ 1,370,394 $ 1,245,670 Less: Provision for expected credit losses 151,167 106,075 Total receivables, net $ 1,219,227 $ 1,139,595 A reconciliation of the beginning and ending amount of our provision for expected credit losses is as follows: (In thousands) Provision for expected credit losses - balance at December 28, 2019 $ 106,075 Cumulative effect of accounting change (ASU 2016-13) 4,606 Additions charged to costs and expenses 54,636 Deductions (14,150) Provision for expected credit losses - balance at September 30, 2020 $ 151,167 During the first nine months of 2020 and 2019, we received total client cash collections of $4.09 billion and $4.23 billion, respectively. Expected Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our condensed consolidated balance sheets as of December 29, 2019. We did not recast comparative periods. A summary of such cumulative effect adjustment is as follows: (In thousands) Increase/(Decrease) Receivables, net $ (4,606) Retained earnings (4,606) The cumulative effect adjustment is the result of providing an allowance on unbilled client receivables, for which we have an unconditional right to invoice and receive payment in the future. Our estimates of expected credit losses for client receivables at both December 29, 2019 and September 30, 2020, were primarily based on historical credit loss experience and adjustments for certain asset-specific risk characteristics (i.e. known client financial hardship or bankruptcy). Exposure to credit losses may increase if our clients are adversely affected by changes in healthcare laws, reimbursement or payor models; economic pressures or uncertainty associated with local or global economic recessions; disruption associated with the COVID-19 pandemic; or other client-specific factors. Although we have historically not experienced significant credit losses, it is possible that there could be an adverse impact from potential adjustments to the carrying amount of client receivables as clients' cash flows are impacted by the COVID-19 pandemic and related economic uncertainty, which may be material.

Investments

Investments	9 Months Ended
	Sep. 30, 2020
Investments [Abstract]
Investments	Investments Available-for-sale investments at September 30, 2020 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 56,855 $ — $ — $ 56,855 Time deposits 19,676 — — 19,676 Commercial Paper 1,600 — — 1,600 Government and corporate bonds 1,150 — — 1,150 Total cash equivalents 79,281 — — 79,281 Short-term investments: Time deposits 21,248 — — 21,248 Commercial paper 259,000 22 (7) 259,015 Government and corporate bonds 192,536 559 (35) 193,060 Total short-term investments 472,784 581 (42) 473,323 Long-term investments: Government and corporate bonds 91,605 180 (78) 91,707 Total available-for-sale investments $ 643,670 $ 761 $ (120) $ 644,311 Available-for-sale investments at December 28, 2019 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 185,666 $ — $ — $ 185,666 Time deposits 64,286 — — 64,286 Total cash equivalents 249,952 — — 249,952 Short-term investments: Time deposits 2,506 — — 2,506 Government and corporate bonds 83,272 52 (11) 83,313 Total short-term investments 85,778 52 (11) 85,819 Long-term investments: Government and corporate bonds 96,186 91 (67) 96,210 Total available-for-sale investments $ 431,916 $ 143 $ (78) $ 431,981 We sold available-for-sale investments for proceeds of $5 million and $181 million during the nine months ended September 30, 2020 and September 28, 2019, respectively, resulting in insignificant gains/losses in each period. Other Investments At September 30, 2020 and December 28, 2019, we had investments in equity securities that do not have readily determinable fair values of $320 million and $314 million, respectively, accounted for in accordance with Accounting Standards Codification Topic ("ASC") 321, Investments-Equity Securities . Such investments are included in "Long-term investments" in our condensed consolidated balance sheets. We did not record any changes in the measurement of such investments during the nine months ended September 30, 2020 and September 28, 2019, respectively. At June 30, 2020 and December 28, 2019, we had investments in equity securities with readily determinable fair values of $41 million and $14 million, respectively, accounted for in accordance with ASC 321. Such investments were included in "Short-term investments" in our condensed consolidated balance sheets. Changes in the measurement of such investments favorably impacted "Other income, net" by $49 million and $76 million for the three and nine months ended September 30, 2020, respectively, and $9 million for both the three and nine months ended September 28, 2019. In August 2020, we sold these investments for cash proceeds of $90 million. At September 30, 2020 and December 28, 2019, we had investments in equity securities reported under the equity method of accounting of $11 million and $9 million, respectively. Such investments are included in "Long-term investments" in our condensed consolidated balance sheets. Impairment Assessment We adopted ASU 2016-13 in the first quarter of 2020, which made certain amendments to the model used to assess available-for-sale debt securities for impairment. Such guidance provides that an available-for-sale debt security is impaired if the fair value of the security is less than its amortized cost basis. A determination is made whether the decline in fair value below the amortized cost basis has resulted from a credit loss or other factors, such as market liquidity or changes in interest rates. Impairment related to credit losses is recognized in net earnings, whereas impairment related to other factors is recognized as a component of accumulated other comprehensive loss, net. During the nine months ended September 30, 2020, we did not recognize any impairment on our available-for-sale debt securities through net earnings.

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt Disclosure	Long-term Debt The following is a summary of indebtedness outstanding: (In thousands) September 30, 2020 December 28, 2019 Credit agreement loans due May 5, 2024 $ 600,000 $ 600,000 Senior notes: Series 2020-A due March 11, 2030 300,000 — Series 2015-A due February 15, 2022 225,000 225,000 Series 2015-B due February 14, 2025 200,000 200,000 Other 11,662 14,162 Total indebtedness 1,336,662 1,039,162 Less: debt issuance costs (644) (780) Long-term debt $ 1,336,018 $ 1,038,382 Credit Agreement As of September 30, 2020, the interest rate on revolving credit loans outstanding under our Credit Agreement was 0.95% based on LIBOR plus the applicable spread. We are exposed to market risk from fluctuations in the variable interest rates on outstanding indebtedness under our Credit Agreement. In order to manage this exposure, we have entered into an interest rate swap agreement to hedge the variability of cash flows associated with such interest obligations. The interest rate swap is designated as a cash flow hedge, which effectively fixes the interest rate on the hedged indebtedness under our Credit Agreement at 3.06%. At September 30, 2020 and December 28, 2019, this swap was in a net liability position with an aggregate fair value of $41 million and $17 million, respectively; which is presented in our condensed consolidated balance sheets in "Other current liabilities" . Series 2020-A Senior Notes In March 2020, we issued $300 million aggregate principal amount of 2.50% senior unsecured Series 2020-A notes (the "Series 2020-A Notes") due March 11, 2030, pursuant to a Master Note Agreement we entered into in November 2019, and subsequently amended on October 8, 2020 (collectively and as amended, the "2019 Shelf Agreement"). Interest on

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements We determine fair value measurements used in our consolidated financial statements based upon the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: • Level 1 – Valuations based on quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. • Level 2 – Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. • Level 3 – Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at September 30, 2020: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 56,855 $ — $ — Time deposits Cash equivalents — 19,676 — Commercial paper Cash equivalents — 1,600 — Government and corporate bonds Cash equivalents — 1,150 — Time deposits Short-term investments — 21,248 — Commercial paper Short-term investments — 259,015 — Government and corporate bonds Short-term investments — 193,060 — Government and corporate bonds Long-term investments — 91,707 — The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at December 28, 2019: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 185,666 $ — $ — Time deposits Cash equivalents — 64,286 — Time deposits Short-term investments — 2,506 — Government and corporate bonds Short-term investments — 83,313 — Government and corporate bonds Long-term investments — 96,210 — Our investments in equity securities with readily determinable fair values accounted for in accordance with ASC 321 were measured and recorded at fair value on a recurring basis using a Level 2 valuation. The fair value of such arrangements was based on quoted prices in active markets, reduced by a percentage reflecting a discount for lack of marketability. Our interest rate swap agreement is measured and recorded at fair value on a recurring basis using a Level 2 valuation. The fair value of such agreement is based on the market standard methodology of netting the discounted expected future variable cash receipts and the discounted future fixed cash payments. The variable cash receipts are based on an expectation of future interest rates derived from observed market interest rate forward curves. Since these inputs are observable in active markets over the terms that the instrument is held, the derivative is classified as Level 2 in the hierarchy. We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. We estimate the fair value of our long-term, variable rate debt using a Level 3 discounted cash flow analysis based on LIBOR rate forward curves. The fair value of our long-term debt at September 30, 2020 and December 28, 2019 was approximately $1.34 billion and $1.07 billion, respectively. The carrying amount of such debt at September 30, 2020 and December 28, 2019 was $1.33 billion and $1.03 billion, respectively.

Gain on Sale of Businesses

Gain on Sale of Businesses	9 Months Ended
	Sep. 30, 2020
Discontinued Operations and Disposal Groups [Abstract]
Gain on Sale of Businesses	Gain on Sale of Businesses Germany and Spain On July 1, 2020, we sold certain of our business operations, primarily conducted in Germany and Spain, to affiliates of CompuGroup Medical SE & Co. KGaA ("CGM"), as a part of our portfolio management strategy. Such operations included the associates, intellectual property, client contracts, other assets, and liabilities related to our medico ® , Selene ® , Soarian Health Archive ® , and Soarian ® Integrated Care solution offerings. We received a sale price of $227 million, which is subject to post-closing adjustments for working capital and certain other adjustments. The following table presents a reconciliation of the sale price to the net gain recognized on the disposed business operations which is included in "Gain on sale of businesses" in our condensed consolidated statements of operations: (In thousands) Sale price $ 226,623 Net assets/(liabilities) removed (7,617) Transaction expenses (5,573) Foreign currency 1,263 Gain on sale of businesses $ 214,696 The following table presents a reconciliation of the sale price to the cash proceeds received from CGM which are included in "Sale of businesses" in our condensed consolidated statements of cash flows: (In thousands) Sale price $ 226,623 VAT and other transaction taxes, net (2,142) Cash received from sale of businesses $ 224,481 Amounts included in our condensed consolidated balance sheets related to the disposed business operations immediately prior to the sale on July 1, 2020 were as follows: (In thousands) Asset/(Liability) Receivables, net $ 7,334 Inventory 65 Prepaid expenses and other 5,759 Property and equipment, net 336 Right-of-use assets 554 Software development costs, net 5,532 Goodwill 7,692 Intangible assets, net 3,687 Accounts payable (1,631) Deferred revenue (16,655) Accrued payroll and tax withholdings (4,545) Other current liabilities (511) Net assets/(liabilities) $ 7,617 Revenue Cycle Outsourcing On August 3, 2020, we sold certain of our revenue cycle outsourcing business operations to affiliates of R1 RCM Inc., as a part of our portfolio management strategy. Such operations included the associates, client contracts, certain other assets, and certain liabilities related to our commercial revenue cycle outsourcing services business. A net gain of $2 million was recognized on the disposed business operations and is included in "Gain on sale of businesses" in our condensed consolidated statements of operations. Amounts included in our condensed consolidated balance sheets related to the disposed business operations immediately prior to the sale on August 3, 2020 were not material to our condensed consolidated financial statements.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesWe determine the tax provision for interim periods using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter we update our estimate of the annual effective tax rate, and if our estimated tax rate changes, we make a cumulative adjustment. Our effective tax rate was 21.7% and 18.9% for the first nine months of 2020 and 2019, respectively. The increase in the effective tax rate in the first nine months of 2020 is primarily due to a decrease in net excess tax benefits recognized as a component of income tax expense in connection with the exercise of stock options and the vesting of restricted share and share unit awards. Also contributing to the increase, are taxes associated with the divestiture transactions that closed in the third quarter of 2020, as further discussed in Note (7).

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows: Three Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 356,676 305,759 $ 1.17 $ 81,935 315,876 $ 0.26 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,607 — 3,237 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 356,676 308,366 $ 1.16 $ 81,935 319,113 $ 0.26 For the three months ended September 30, 2020 and September 28, 2019, options to purchase 3.9 million and 7.7 million shares of common stock at per share prices ranging from $55.24 to $76.49 and $54.87 to $75.83, respectively, were outstanding but were not included in the computation of diluted earnings per share because they were anti-dilutive. Nine Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 638,583 306,759 $ 2.08 $ 375,123 320,282 $ 1.17 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,365 — 3,079 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 638,583 309,124 $ 2.07 $ 375,123 323,361 $ 1.16 For the nine months ended September 30, 2020 and September 28, 2019, options to purchase 4.4 million and 10.1 million shares of common stock at per share prices ranging from $52.32 to $76.49 and $51.87 to $75.83, respectively, were outstanding but were not included in the computation of diluted earnings per share because they were anti-dilutive.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Shareholders' Equity and Share-based Payments	Share-Based Compensation and Equity Stock Options Stock option activity for the nine months ended September 30, 2020 was as follows: (In thousands, except per share and term data) Number of Weighted- Aggregate Weighted-Average Outstanding at beginning of year 15,416 $ 56.36 Granted 3 72.36 Exercised (4,009) 50.67 Forfeited and expired (228) 61.32 Outstanding as of September 30, 2020 11,182 58.31 $ 156,372 5.70 Exercisable as of September 30, 2020 7,248 $ 56.87 $ 111,738 4.85 The weighted-average assumptions used to estimate the fair value, under the Black-Scholes-Merton pricing model, of stock options granted during the nine months ended September 30, 2020 were as follows: Expected volatility (%) 24.5 % Expected dividend rate (%) 1 % Expected term (yrs) 6 Risk-free rate (%) 1.1 % Fair value per option $ 16.64 As of September 30, 2020, there was $58 million of total unrecognized compensation cost related to stock options granted under all plans. That cost is expected to be recognized over a weighted-average period of 2.12 years. Non-vested Shares and Share Units Non-vested share and share unit activity for the nine months ended September 30, 2020 was as follows: (In thousands, except per share data) Number of Shares Weighted-Average Outstanding at beginning of year 2,634 $ 65.30 Granted 2,520 69.99 Vested (946) 66.30 Forfeited (97) 67.24 Outstanding as of September 30, 2020 4,111 $ 67.90 As of September 30, 2020, there was $223 million of total unrecognized compensation cost related to non-vested share and share unit awards granted under all plans. That cost is expected to be recognized over a weighted-average period of 1.96 years. Share-Based Compensation Cost The following table presents total compensation expense recognized with respect to stock options, non-vested shares and share units, and our associate stock purchase plan: Three Months Ended Nine Months Ended (In thousands) 2020 2019 2020 2019 Stock option and non-vested share and share unit compensation expense $ 37,920 $ 30,537 $ 110,500 $ 73,421 Associate stock purchase plan expense 1,367 1,321 4,195 4,612 Amounts capitalized in software development costs, net of amortization (1,150) (76) (2,971) 70 Amounts charged against earnings, before income tax benefit $ 38,137 $ 31,782 $ 111,724 $ 78,103 Amount of related income tax benefit recognized in earnings $ 7,818 $ 6,330 $ 22,452 $ 14,888 Treasury Stock Under our current share repurchase program, which was initially approved by our Board of Directors in May 2017 and most recently amended in December 2019, the Company is authorized to repurchase up to $3.70 billion of shares of our common stock, excluding transaction costs. The repurchases are to be effectuated in the open market, by block purchase, in privately negotiated transactions, or through other transactions managed by broker-dealers. No time limit was set for the completion of the program. During the nine months ended September 30, 2020, we repurchased 9.2 million shares for total consideration of $650 million under the program. The shares were recorded as treasury stock and accounted for under the cost method. No repurchased shares have been retired. As of September 30, 2020, $1.03 billion remains available for repurchase under the program. Dividends On September 10, 2020, our Board of Directors declared a cash dividend of $0.18 per share on our issued and outstanding common stock, which was paid on October 13, 2020 to shareholders of record as of September 25, 2020. On May 21, 2020, our Board of Directors declared a cash dividend of $0.18 per share on our issued and outstanding common stock, which was paid on July 17, 2020 to shareholders of record as of June 5, 2020. On March 19, 2020, our Board of Directors declared a cash dividend of $0.18 per share on our issued and outstanding common stock, which was paid on April 17, 2020 to shareholders of record as of April 3, 2020. In connection with the declaration of such dividends, our non-vested shares and share units are entitled to dividend equivalents, which will be payable to the holder subject to, and upon vesting of, the underlying awards. Our outstanding stock options are not entitled to dividend or dividend equivalents. At both September 30, 2020 and December 28, 2019, our condensed consolidated balance sheets included liabilities for dividends payable of $56 million, which are included in "Other current liabilities". Accumulated Other Comprehensive Loss, Net (AOCI) The components of AOCI, net of tax, were as follows: Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 28, 2019 $ (106,347) $ (12,578) $ 265 $ (118,660) Other comprehensive income (loss) before reclassifications (20,546) (20,430) (849) (41,825) Amounts reclassified from AOCI — 1,122 — 1,122 Balance at March 31, 2020 (126,893) (31,886) (584) (159,363) Other comprehensive income (loss) before reclassifications 9,197 (3,205) 1,502 7,494 Amounts reclassified from AOCI — 2,198 — 2,198 Balance at June 30, 2020 (117,696) (32,893) 918 (149,671) Other comprehensive income (loss) before reclassifications 9,611 (289) (220) 9,102 Amounts reclassified from AOCI — 2,554 — 2,554 Balance at September 30, 2020 $ (108,085) $ (30,628) $ 698 $ (138,015) Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 29, 2018 $ (102,939) $ — $ (613) $ (103,552) Other comprehensive income (loss) before reclassifications 2,321 — 637 2,958 Amounts reclassified from AOCI — — — — Balance at March 30, 2019 (100,618) — 24 (100,594) Other comprehensive income (loss) before reclassifications (100) (12,223) 216 (12,107) Amounts reclassified from AOCI — (147) — (147) Balance at June 29, 2019 (100,718) (12,370) 240 (112,848) Other comprehensive income (loss) before reclassifications (11,679) (4,135) 17 (15,797) Amounts reclassified from AOCI — 98 (3) 95 Balance at September 28, 2019 $ (112,397) $ (16,407) $ 254 $ (128,550) The effects on net earnings of amounts reclassified from AOCI were as follows: (In thousands) Three Months Ended Nine Months Ended AOCI Component Location 2020 2019 2020 2019 Unrealized loss on cash flow hedge Other income, net $ (3,213) $ (122) $ (7,383) $ 58 Income taxes 659 24 1,509 (9) Net of tax (2,554) (98) (5,874) 49 Unrealized holding gain (loss) on available-for-sale investments Other income, net — 4 — 4 Income taxes — (1) — (1) Net of tax — 3 — 3 Total amount reclassified, net of tax $ (2,554) $ (95) $ (5,874) $ 52

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies Disclosure	Contingencies We accrue estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies ("ASC 450"). No less than quarterly, and as facts and circumstances change, we review the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any one or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our business, results of operations, cash flows or financial condition. As previously disclosed, we continue to be in dispute with Fujitsu Services Limited ("Fujitsu") regarding Fujitsu's obligation to pay amounts to us due upon the termination of a subcontract, including client receivables, in connection with Fujitsu's contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England. The NHS terminated its contract with Fujitsu, which gave rise to the termination of our subcontract with Fujitsu. We filed a request for arbitration with the London Court of International Arbitration on April 22, 2019 seeking damages. On December 30, 2019, Fujitsu filed its Defense and Counterclaim (the "Counterclaim") in response. In its Counterclaim, Fujitsu defends against our claim in full and argues that we are liable to Fujitsu for: (i) £306 million in damages based on our alleged fraudulent misrepresentations inducing Fujitsu to enter into the subcontract; or (ii) alternatively, £173.8 million in damages based on our alleged breaches of the subcontract. We filed our response to Fujitsu's Counterclaim on May 1, 2020, to which they have now responded. We believe that Fujitsu's claims are without merit and will vigorously defend against them, and we continue to believe that we have valid and equitable grounds for recovery of the disputed client receivables; however, there can be no assurances as to the outcome of the dispute. As previously disclosed, we recorded a pre-tax charge of $45 million in the fourth quarter of 2018 to provide an allowance against the disputed client receivables reflecting the uncertainty in collection of such receivables and related litigation risk resulting from the conclusion of the non-binding alternative dispute resolution procedures, which occurred before we filed our request for arbitration. We have not concluded that a loss related to the new claims raised by Fujitsu in the Counterclaim is probable, nor have we accrued a liability related to these claims beyond the previously reported pre-tax charge recorded in the fourth quarter of 2018. Although we believe a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Counterclaim given that the dispute is in the early stages of the arbitration process. Arbitration is currently scheduled to occur in April 2022. Cerner Health Services, Inc. ("Cerner HS"), a wholly owned subsidiary of Cerner Corporation, filed a lawsuit in the Chester County, Pennsylvania, Court of Common Pleas against NextGen Healthcare Information Systems, LLC ("NextGen") relating to a dispute arising out of a supplier relationship initially established between Siemens Health Services, Inc. ("Health Services") and NextGen prior to the acquisition of the assets of Health Services by Cerner HS in 2015. In September 2017, the court issued a preliminary injunction to prevent NextGen from refusing to honor certain contractual obligations to support Cerner HS's clients who use NextGen ambulatory EHR solutions. In September 2018, NextGen filed a counterclaim alleging breach of contract and tortious interference but did not specify its damages. In August 2019, NextGen provided an expert report alleging profit disgorgement damages of $135 million or, alternatively, $30.5 million in lost profit damages, but the report did not discuss how our actions allegedly caused NextGen's damages. In December 2019, we deposed NextGen's expert, gaining additional clarity on categories of alleged damages but not on the alleged theories of liability. A jury trial is set to begin on January 25, 2021. We believe NextGen's claims are without merit and will vigorously defend against them; however, there can be no assurances as to the outcome of the dispute. We have not concluded that a loss related to the claims raised by NextGen in its counterclaim is probable, nor have we accrued a liability related to these claims. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by NextGen's expert, and the continued lack of clarity on the causal connection between Cerner Corporation's and Cerner HS's actions and any alleged damages. The terms of our agreements with our clients generally provide for limited indemnification of such clients against losses, expenses and liabilities arising from third party or other claims based on, among other things, alleged infringement by our solutions of an intellectual property right of third parties or damages caused by data privacy breaches or system interruptions. The terms of such indemnification often limit the scope of and remedies for such indemnification obligations and generally include, as applicable, a right to replace or modify an infringing solution. For several reasons, including the lack of a sufficient number of prior indemnification claims relating to IP infringement, data privacy breaches or system interruptions, the inherent uncertainty stemming from such claims, and the lack of a monetary liability limit for such claims under the terms of the corresponding agreements with our clients, we cannot determine the maximum amount of potential future payments, if any, related to such indemnification provisions. In addition to commitments and obligations in the ordinary course of business, we are involved in various other legal proceedings and claims that arise in the ordinary course of business, including for example, employment and client disputes and litigation alleging solution and implementation defects, personal injury, intellectual property infringement, violations of law, breaches of contract and warranties, and compliance audits by various government agencies. Many of these proceedings are at preliminary stages and many seek an indeterminate amount of damages. At this time, we do not believe the range of potential losses under any claims to be material to our consolidated financial statements.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Reporting	Segment ReportingWe have two operating segments, Domestic and International. Revenues are derived primarily from the sale of clinical, financial and administrative information solutions and services. The cost of revenues includes the cost of third-party consulting services, computer hardware, devices and sublicensed software purchased from manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. Operating expenses incurred by the geographic business segments consist of sales and client service expenses including salaries of sales and client service personnel, expenses associated with our managed services business, marketing expenses, communications expenses and unreimbursed travel expenses. "Other" includes expenses that have not been allocated to the operating segments, such as software development, general and administrative expenses, certain organizational restructuring and other expense, share-based compensation expense, and certain amortization and depreciation. "Other" also includes gains or losses recognized on the divestiture of businesses. Performance of the segments is assessed at the operating earnings level by our chief operating decision maker, who is our Chief Executive Officer. Items such as interest, income taxes, capital expenditures and total assets are managed at the consolidated level and thus are not included in our operating segment disclosures. Accounting policies for each of the reportable segments are the same as those used on a consolidated basis. The following table presents a summary of our operating segments and other expense for the three and nine months ended September 30, 2020 and September 28, 2019: (In thousands) Domestic International Other Total Three Months Ended 2020 Revenues $ 1,230,769 $ 137,904 $ — $ 1,368,673 Costs of revenue 219,938 11,951 — 231,889 Operating expenses 566,777 58,626 316,430 941,833 Total costs and expenses 786,715 70,577 316,430 1,173,722 Gain on sale of businesses — — 216,869 216,869 Operating earnings (loss) $ 444,054 $ 67,327 $ (99,561) $ 411,820 (In thousands) Domestic International Other Total Three Months Ended 2019 Revenues $ 1,265,263 $ 164,165 $ — $ 1,429,428 Costs of revenue 246,634 25,144 — 271,778 Operating expenses 639,590 68,153 361,130 1,068,873 Total costs and expenses 886,224 93,297 361,130 1,340,651 Operating earnings (loss) $ 379,039 $ 70,868 $ (361,130) $ 88,777 (In thousands) Domestic International Other Total Nine Months Ended 2020 Revenues $ 3,645,397 $ 465,366 $ — $ 4,110,763 Costs of revenue 638,284 59,984 — 698,268 Operating expenses 1,724,545 182,594 985,131 2,892,270 Total costs and expenses 2,362,829 242,578 985,131 3,590,538 Gain on sale of businesses — — 216,869 216,869 Operating earnings (loss) $ 1,282,568 $ 222,788 $ (768,262) $ 737,094 (In thousands) Domestic International Other Total Nine Months Ended 2019 Revenues $ 3,762,205 $ 488,161 $ — $ 4,250,366 Costs of revenue 719,119 74,536 — 793,655 Operating expenses 1,817,244 209,580 1,012,049 3,038,873 Total costs and expenses 2,536,363 284,116 1,012,049 3,832,528 Operating earnings (loss) $ 1,225,842 $ 204,045 $ (1,012,049) $ 417,838

Organization, Consolidation and

Organization, Consolidation and Presentation of Financial Statements (Policies)	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting, Policy [Policy Text Block]	The condensed consolidated financial statements were prepared using GAAP
Fiscal Period, Policy [Policy Text Block]	Prior to fiscal year 2020, our third fiscal quarter ended on the Saturday closest to September 30. The third quarter and year-to-date periods for 2019 presented herein consisted of 91 days and 273 days, respectively, and ended on September 28, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, the third quarter and year-to-date periods for 2020 presented herein consisted of 92 days and 277 days, respectively, and ended on September 30, 2020. All references to periods in these notes to condensed consolidated financial statements represent the respective periods described above ending on September 30, 2020 and September 28, 2019, unless otherwise noted.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	Disaggregation of Revenue The following tables present revenues disaggregated by our business models: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Licensed software $ 159,327 $ 12,367 $ 171,694 $ 144,599 $ 9,934 $ 154,533 Technology resale 45,217 1,896 47,113 65,103 5,072 70,175 Subscriptions 87,878 5,529 93,407 85,230 6,674 91,904 Professional services 433,127 46,768 479,895 446,562 60,893 507,455 Managed services 280,827 31,017 311,844 272,933 29,502 302,435 Support and maintenance 219,682 40,296 259,978 227,131 50,163 277,294 Reimbursed travel 4,711 31 4,742 23,705 1,927 25,632 Total revenues $ 1,230,769 $ 137,904 $ 1,368,673 $ 1,265,263 $ 164,165 $ 1,429,428 Nine Months Ended 2020 2019 (In thousands) Domestic Segment International Segment Total Domestic Segment International Segment Total Licensed software $ 444,774 $ 37,114 $ 481,888 $ 466,105 $ 40,018 $ 506,123 Technology resale 126,042 14,675 140,717 169,112 17,338 186,450 Subscriptions 260,095 19,749 279,844 246,505 19,460 265,965 Professional services 1,295,759 156,564 1,452,323 1,313,701 169,500 1,483,201 Managed services 836,242 92,114 928,356 818,818 85,661 904,479 Support and maintenance 663,399 144,296 807,695 679,214 151,454 830,668 Reimbursed travel 19,086 854 19,940 68,750 4,730 73,480 Total revenues $ 3,645,397 $ 465,366 $ 4,110,763 $ 3,762,205 $ 488,161 $ 4,250,366 The following tables present our revenues disaggregated by timing of revenue recognition: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Revenue recognized over time $ 1,143,515 $ 132,891 $ 1,276,406 $ 1,143,470 $ 155,017 $ 1,298,487 Revenue recognized at a point in time 87,254 5,013 92,267 121,793 9,148 130,941 Total revenues $ 1,230,769 $ 137,904 $ 1,368,673 $ 1,265,263 $ 164,165 $ 1,429,428 Nine Months Ended 2020 2019 (In thousands) Domestic Segment International Segment Total Domestic Segment International Segment Total Revenue recognized over time $ 3,410,827 $ 437,791 $ 3,848,618 $ 3,403,965 $ 445,320 $ 3,849,285 Revenue recognized at a point in time 234,570 27,575 262,145 358,240 42,841 401,081 Total revenues $ 3,645,397 $ 465,366 $ 4,110,763 $ 3,762,205 $ 488,161 $ 4,250,366

Receivables (Tables)

Receivables (Tables)	9 Months Ended
	Sep. 30, 2020
Receivables [Abstract]
Summary of Net Receivables	A summary of net receivables is as follows: (In thousands) September 30, 2020 December 28, 2019 Client receivables $ 1,370,394 $ 1,245,670 Less: Provision for expected credit losses 151,167 106,075 Total receivables, net $ 1,219,227 $ 1,139,595
Accounts Receivable, Allowance for Credit Loss	A reconciliation of the beginning and ending amount of our provision for expected credit losses is as follows: (In thousands) Provision for expected credit losses - balance at December 28, 2019 $ 106,075 Cumulative effect of accounting change (ASU 2016-13) 4,606 Additions charged to costs and expenses 54,636 Deductions (14,150) Provision for expected credit losses - balance at September 30, 2020 $ 151,167
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	A summary of such cumulative effect adjustment is as follows: (In thousands) Increase/(Decrease) Receivables, net $ (4,606) Retained earnings (4,606)

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2020
Investments [Abstract]
Schedule of available-for-sale investments	Available-for-sale investments at September 30, 2020 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 56,855 $ — $ — $ 56,855 Time deposits 19,676 — — 19,676 Commercial Paper 1,600 — — 1,600 Government and corporate bonds 1,150 — — 1,150 Total cash equivalents 79,281 — — 79,281 Short-term investments: Time deposits 21,248 — — 21,248 Commercial paper 259,000 22 (7) 259,015 Government and corporate bonds 192,536 559 (35) 193,060 Total short-term investments 472,784 581 (42) 473,323 Long-term investments: Government and corporate bonds 91,605 180 (78) 91,707 Total available-for-sale investments $ 643,670 $ 761 $ (120) $ 644,311 Available-for-sale investments at December 28, 2019 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 185,666 $ — $ — $ 185,666 Time deposits 64,286 — — 64,286 Total cash equivalents 249,952 — — 249,952 Short-term investments: Time deposits 2,506 — — 2,506 Government and corporate bonds 83,272 52 (11) 83,313 Total short-term investments 85,778 52 (11) 85,819 Long-term investments: Government and corporate bonds 96,186 91 (67) 96,210 Total available-for-sale investments $ 431,916 $ 143 $ (78) $ 431,981

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Debt	The following is a summary of indebtedness outstanding: (In thousands) September 30, 2020 December 28, 2019 Credit agreement loans due May 5, 2024 $ 600,000 $ 600,000 Senior notes: Series 2020-A due March 11, 2030 300,000 — Series 2015-A due February 15, 2022 225,000 225,000 Series 2015-B due February 14, 2025 200,000 200,000 Other 11,662 14,162 Total indebtedness 1,336,662 1,039,162 Less: debt issuance costs (644) (780) Long-term debt $ 1,336,018 $ 1,038,382

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at September 30, 2020: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 56,855 $ — $ — Time deposits Cash equivalents — 19,676 — Commercial paper Cash equivalents — 1,600 — Government and corporate bonds Cash equivalents — 1,150 — Time deposits Short-term investments — 21,248 — Commercial paper Short-term investments — 259,015 — Government and corporate bonds Short-term investments — 193,060 — Government and corporate bonds Long-term investments — 91,707 — The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at December 28, 2019: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 185,666 $ — $ — Time deposits Cash equivalents — 64,286 — Time deposits Short-term investments — 2,506 — Government and corporate bonds Short-term investments — 83,313 — Government and corporate bonds Long-term investments — 96,210 —

Gain on Sale of Businesses (Tab

Gain on Sale of Businesses (Tables)	9 Months Ended
	Sep. 30, 2020
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	The following table presents a reconciliation of the sale price to the net gain recognized on the disposed business operations which is included in "Gain on sale of businesses" in our condensed consolidated statements of operations: (In thousands) Sale price $ 226,623 Net assets/(liabilities) removed (7,617) Transaction expenses (5,573) Foreign currency 1,263 Gain on sale of businesses $ 214,696 The following table presents a reconciliation of the sale price to the cash proceeds received from CGM which are included in "Sale of businesses" in our condensed consolidated statements of cash flows: (In thousands) Sale price $ 226,623 VAT and other transaction taxes, net (2,142) Cash received from sale of businesses $ 224,481 Amounts included in our condensed consolidated balance sheets related to the disposed business operations immediately prior to the sale on July 1, 2020 were as follows: (In thousands) Asset/(Liability) Receivables, net $ 7,334 Inventory 65 Prepaid expenses and other 5,759 Property and equipment, net 336 Right-of-use assets 554 Software development costs, net 5,532 Goodwill 7,692 Intangible assets, net 3,687 Accounts payable (1,631) Deferred revenue (16,655) Accrued payroll and tax withholdings (4,545) Other current liabilities (511) Net assets/(liabilities) $ 7,617

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020
Earnings Per Share [Abstract]
Reconciliation Of The Numerators And The Denominators Of The Basic And Diluted Per Share	A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows: Three Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 356,676 305,759 $ 1.17 $ 81,935 315,876 $ 0.26 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,607 — 3,237 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 356,676 308,366 $ 1.16 $ 81,935 319,113 $ 0.26	Nine Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 638,583 306,759 $ 2.08 $ 375,123 320,282 $ 1.17 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,365 — 3,079 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 638,583 309,124 $ 2.07 $ 375,123 323,361 $ 1.16

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule Of Stock Options Activity	Stock option activity for the nine months ended September 30, 2020 was as follows: (In thousands, except per share and term data) Number of Weighted- Aggregate Weighted-Average Outstanding at beginning of year 15,416 $ 56.36 Granted 3 72.36 Exercised (4,009) 50.67 Forfeited and expired (228) 61.32 Outstanding as of September 30, 2020 11,182 58.31 $ 156,372 5.70 Exercisable as of September 30, 2020 7,248 $ 56.87 $ 111,738 4.85
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The weighted-average assumptions used to estimate the fair value, under the Black-Scholes-Merton pricing model, of stock options granted during the nine months ended September 30, 2020 were as follows: Expected volatility (%) 24.5 % Expected dividend rate (%) 1 % Expected term (yrs) 6 Risk-free rate (%) 1.1 % Fair value per option $ 16.64
Schedule of Share-based Compensation, Restricted Stock Activity	Non-vested share and share unit activity for the nine months ended September 30, 2020 was as follows: (In thousands, except per share data) Number of Shares Weighted-Average Outstanding at beginning of year 2,634 $ 65.30 Granted 2,520 69.99 Vested (946) 66.30 Forfeited (97) 67.24 Outstanding as of September 30, 2020 4,111 $ 67.90
Compensation Expense Recognized In The Condensed Consolidated Statements Of Operations	The following table presents total compensation expense recognized with respect to stock options, non-vested shares and share units, and our associate stock purchase plan: Three Months Ended Nine Months Ended (In thousands) 2020 2019 2020 2019 Stock option and non-vested share and share unit compensation expense $ 37,920 $ 30,537 $ 110,500 $ 73,421 Associate stock purchase plan expense 1,367 1,321 4,195 4,612 Amounts capitalized in software development costs, net of amortization (1,150) (76) (2,971) 70 Amounts charged against earnings, before income tax benefit $ 38,137 $ 31,782 $ 111,724 $ 78,103 Amount of related income tax benefit recognized in earnings $ 7,818 $ 6,330 $ 22,452 $ 14,888
Schedule of Accumulated Other Comprehensive Income (Loss)	The components of AOCI, net of tax, were as follows: Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 28, 2019 $ (106,347) $ (12,578) $ 265 $ (118,660) Other comprehensive income (loss) before reclassifications (20,546) (20,430) (849) (41,825) Amounts reclassified from AOCI — 1,122 — 1,122 Balance at March 31, 2020 (126,893) (31,886) (584) (159,363) Other comprehensive income (loss) before reclassifications 9,197 (3,205) 1,502 7,494 Amounts reclassified from AOCI — 2,198 — 2,198 Balance at June 30, 2020 (117,696) (32,893) 918 (149,671) Other comprehensive income (loss) before reclassifications 9,611 (289) (220) 9,102 Amounts reclassified from AOCI — 2,554 — 2,554 Balance at September 30, 2020 $ (108,085) $ (30,628) $ 698 $ (138,015) Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 29, 2018 $ (102,939) $ — $ (613) $ (103,552) Other comprehensive income (loss) before reclassifications 2,321 — 637 2,958 Amounts reclassified from AOCI — — — — Balance at March 30, 2019 (100,618) — 24 (100,594) Other comprehensive income (loss) before reclassifications (100) (12,223) 216 (12,107) Amounts reclassified from AOCI — (147) — (147) Balance at June 29, 2019 (100,718) (12,370) 240 (112,848) Other comprehensive income (loss) before reclassifications (11,679) (4,135) 17 (15,797) Amounts reclassified from AOCI — 98 (3) 95 Balance at September 28, 2019 $ (112,397) $ (16,407) $ 254 $ (128,550)
Reclassification out of Accumulated Other Comprehensive Income	The effects on net earnings of amounts reclassified from AOCI were as follows: (In thousands) Three Months Ended Nine Months Ended AOCI Component Location 2020 2019 2020 2019 Unrealized loss on cash flow hedge Other income, net $ (3,213) $ (122) $ (7,383) $ 58 Income taxes 659 24 1,509 (9) Net of tax (2,554) (98) (5,874) 49 Unrealized holding gain (loss) on available-for-sale investments Other income, net — 4 — 4 Income taxes — (1) — (1) Net of tax — 3 — 3 Total amount reclassified, net of tax $ (2,554) $ (95) $ (5,874) $ 52

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Summary of the Operating Information	The following table presents a summary of our operating segments and other expense for the three and nine months ended September 30, 2020 and September 28, 2019: (In thousands) Domestic International Other Total Three Months Ended 2020 Revenues $ 1,230,769 $ 137,904 $ — $ 1,368,673 Costs of revenue 219,938 11,951 — 231,889 Operating expenses 566,777 58,626 316,430 941,833 Total costs and expenses 786,715 70,577 316,430 1,173,722 Gain on sale of businesses — — 216,869 216,869 Operating earnings (loss) $ 444,054 $ 67,327 $ (99,561) $ 411,820 (In thousands) Domestic International Other Total Three Months Ended 2019 Revenues $ 1,265,263 $ 164,165 $ — $ 1,429,428 Costs of revenue 246,634 25,144 — 271,778 Operating expenses 639,590 68,153 361,130 1,068,873 Total costs and expenses 886,224 93,297 361,130 1,340,651 Operating earnings (loss) $ 379,039 $ 70,868 $ (361,130) $ 88,777 (In thousands) Domestic International Other Total Nine Months Ended 2020 Revenues $ 3,645,397 $ 465,366 $ — $ 4,110,763 Costs of revenue 638,284 59,984 — 698,268 Operating expenses 1,724,545 182,594 985,131 2,892,270 Total costs and expenses 2,362,829 242,578 985,131 3,590,538 Gain on sale of businesses — — 216,869 216,869 Operating earnings (loss) $ 1,282,568 $ 222,788 $ (768,262) $ 737,094 (In thousands) Domestic International Other Total Nine Months Ended 2019 Revenues $ 3,762,205 $ 488,161 $ — $ 4,250,366 Costs of revenue 719,119 74,536 — 793,655 Operating expenses 1,817,244 209,580 1,012,049 3,038,873 Total costs and expenses 2,536,363 284,116 1,012,049 3,832,528 Operating earnings (loss) $ 1,225,842 $ 204,045 $ (1,012,049) $ 417,838

Policies (Details)

Policies (Details)	9 Months Ended
	Sep. 30, 2020
Interim Statement Presentation [Line Items]
Basis of Accounting, Policy [Policy Text Block]	The condensed consolidated financial statements were prepared using GAAP
Use of Estimates, Policy [Policy Text Block]	These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses
Fiscal Period, Policy [Policy Text Block]	Prior to fiscal year 2020, our third fiscal quarter ended on the Saturday closest to September 30. The third quarter and year-to-date periods for 2019 presented herein consisted of 91 days and 273 days, respectively, and ended on September 28, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, the third quarter and year-to-date periods for 2020 presented herein consisted of 92 days and 277 days, respectively, and ended on September 30, 2020. All references to periods in these notes to condensed consolidated financial statements represent the respective periods described above ending on September 30, 2020 and September 28, 2019, unless otherwise noted.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform, such as the upcoming discontinuance of the London Interbank Offered Rate ("LIBOR"). The accommodations within ASU 2020-04 may be applied prospectively from the beginning of our 2020 first quarter through December 31, 2022. We are currently evaluating the effect that ASU 2020-04 may have on our contracts that reference LIBOR, specifically, our Third Amended and Restated Credit Agreement (as amended, the "Credit Agreement") and related interest rate swap. As of the date of this filing, we have not elected to apply any of the provisions of this standard.
Accounting Standards Update 2018-18 [Member]
Interim Statement Presentation [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description	In November 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies when transactions between participants in a collaborative arrangement are within the scope of the FASB's recent revenue standard (Topic 606). Such guidance clarifies revenue recognition and financial statement presentation for transactions between collaboration participants. We adopted ASU 2018-18 in the first quarter of 2020. Such guidance did not have an impact on our consolidated financial statements and related disclosures.

Interim Statement Presentatio_2

Interim Statement Presentation (Details) $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
CARES Act Deferred Remittance of Employer Payroll Tax	$ 56

Disaggregation of Revenue (Deta

Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019	Sep. 30, 2020	Sep. 28, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 1,368,673	$ 1,429,428	$ 4,110,763	$ 4,250,366
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,276,406	1,298,487	3,848,618	3,849,285
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenues	92,267	130,941	262,145	401,081
Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	1,230,769	1,265,263	3,645,397	3,762,205
Domestic Segment | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,143,515	1,143,470	3,410,827	3,403,965
Domestic Segment | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenues	87,254	121,793	234,570	358,240
International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	137,904	164,165	465,366	488,161
International Segment [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenues	132,891	155,017	437,791	445,320
International Segment [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenues	5,013	9,148	27,575	42,841
Sales Revenue, Licensed Software, Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	171,694	154,533	481,888	506,123
Sales Revenue, Licensed Software, Net [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	159,327	144,599	444,774	466,105
Sales Revenue, Licensed Software, Net [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	12,367	9,934	37,114	40,018
Sales Revenue, Technology Resale, Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	47,113	70,175	140,717	186,450
Sales Revenue, Technology Resale, Net [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	45,217	65,103	126,042	169,112
Sales Revenue, Technology Resale, Net [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,896	5,072	14,675	17,338
Sales Revenue, Subscriptions, Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	93,407	91,904	279,844	265,965
Sales Revenue, Subscriptions, Net [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	87,878	85,230	260,095	246,505
Sales Revenue, Subscriptions, Net [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	5,529	6,674	19,749	19,460
Sales Revenue, Professional Services, Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	479,895	507,455	1,452,323	1,483,201
Sales Revenue, Professional Services, Net [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	433,127	446,562	1,295,759	1,313,701
Sales Revenue, Professional Services, Net [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	46,768	60,893	156,564	169,500
Sales Revenue, Managed Services, Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	311,844	302,435	928,356	904,479
Sales Revenue, Managed Services, Net [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	280,827	272,933	836,242	818,818
Sales Revenue, Managed Services, Net [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	31,017	29,502	92,114	85,661
Sales Revenue, Support and Maintenance Services, Net [Member]
Disaggregation of Revenue [Line Items]
Revenues	259,978	277,294	807,695	830,668
Sales Revenue, Support and Maintenance Services, Net [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	219,682	227,131	663,399	679,214
Sales Revenue, Support and Maintenance Services, Net [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	40,296	50,163	144,296	151,454
Sales Revenue, Reimbursement Revenue [Member]
Disaggregation of Revenue [Line Items]
Revenues	4,742	25,632	19,940	73,480
Sales Revenue, Reimbursement Revenue [Member] | Domestic Segment
Disaggregation of Revenue [Line Items]
Revenues	4,711	23,705	19,086	68,750
Sales Revenue, Reimbursement Revenue [Member] | International Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 31	$ 1,927	$ 854	$ 4,730

Performance Obligation (Details

Performance Obligation (Details) $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
Revenue Recognition [Line Items]
Revenue, Remaining Performance Obligation	$ 13,010
Contract with Customer, Liability, Revenue Recognized	$ 306
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation	we expect to recognize approximately 30% of the revenue over the next 12 months and the remainder thereafter

Revenue from Contracts with C_3

Revenue from Contracts with Customers (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019	Sep. 30, 2020	Sep. 28, 2019
Revenue from Contract with Customer [Abstract]
Segment Reporting, Disclosure of Major Customers	19	12	17	11
Credit Concentration Risk [Member]
Revenue from Contract with Customer [Abstract]
Concentration Risk, Percentage			14.00%
Concentration Risk [Line Items]
Concentration Risk, Percentage			14.00%

Receivables (Narrative) (Detail

Receivables (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019
Receivables [Abstract]
Client cash collections	$ 4,090	$ 4,230
Accounting Standards Update 2016-13 [Member]
Receivables [Abstract]
New Accounting Pronouncement or Change in Accounting Principle, Description	In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our condensed consolidated balance sheets as of December 29, 2019. We did not recast comparative periods.
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description	In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our condensed consolidated balance sheets as of December 29, 2019. We did not recast comparative periods.

Receivables (Summary Of Net Rec

Receivables (Summary Of Net Receivables) (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 28, 2019
Receivables [Abstract]
Gross accounts receivable	$ 1,370,394	$ 1,245,670
Less: Allowance for doubtful accounts	151,167	106,075
Total receivables, net	$ 1,219,227	$ 1,139,595

Schedule of Valuation and Quali

Schedule of Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 28, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Accounts Receivable, Credit Loss Expense (Reversal)	$ 54,636
Accounts Receivable, Allowance for Credit Loss, Writeoff	(14,150)
Accounts Receivable, Allowance for Credit Loss	151,167	$ 106,075
Accounting Standards Update 2016-13 [Member] | Cumulative Effect, Period of Adoption, Adjustment
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment	$ 4,606

Cumulative Effect Transition (D

Cumulative Effect Transition (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 28, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings	$ 6,402,220	$ 5,934,909
Receivables, Net	$ 1,219,227	1,139,595
Accounting Standards Update 2016-13 [Member] | Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings		(4,606)
Receivables, Net		$ (4,606)

Investments (Narrative) (Detail

Investments (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 28, 2019	Jun. 30, 2020	Dec. 28, 2019
Investments [Abstract]
Proceeds from Sale of Available-for-sale Securities		$ 5	$ 181
Equity Securities without Readily Determinable Fair Value, Amount	$ 320	320			$ 314
Equity Securities, FV-NI				$ 41	14
Equity Securities, FV-NI, Unrealized Gain	49	76	$ 9
Equity Method Investments	$ 11	11			$ 9
Proceeds from Sale of Equity Securities with Readily Determinable Fair Values		$ 90

Investments (Details)

Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 28, 2019
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	$ 643,670	$ 431,916
Gross Unrealized Gains	761	143
Gross Unrealized Losses	(120)	(78)
Debt Securities, Available-for-sale	644,311	431,981
Cash equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	79,281	249,952
Debt Securities, Available-for-sale	79,281	249,952
Cash equivalents [Member] | Money market funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	56,855	185,666
Debt Securities, Available-for-sale	56,855	185,666
Cash equivalents [Member] | Time deposits [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	19,676	64,286
Debt Securities, Available-for-sale	19,676	64,286
Cash equivalents [Member] | Commercial paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	1,600
Debt Securities, Available-for-sale	1,600
Cash equivalents [Member] | Government and corporate bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	1,150
Debt Securities, Available-for-sale	1,150
Short-term investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	472,784	85,778
Gross Unrealized Gains	581	52
Gross Unrealized Losses	(42)	(11)
Debt Securities, Available-for-sale	473,323	85,819
Short-term investments [Member] | Time deposits [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	21,248	2,506
Debt Securities, Available-for-sale	21,248	2,506
Short-term investments [Member] | Commercial paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	259,000
Gross Unrealized Gains	22
Gross Unrealized Losses	(7)
Debt Securities, Available-for-sale	259,015
Short-term investments [Member] | Government and corporate bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	192,536	83,272
Gross Unrealized Gains	559	52
Gross Unrealized Losses	(35)	(11)
Debt Securities, Available-for-sale	193,060	83,313
Long-term investments [Member] | Government and corporate bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	91,605	96,186
Gross Unrealized Gains	180	91
Gross Unrealized Losses	(78)	(67)
Debt Securities, Available-for-sale	$ 91,707	$ 96,210

Schedule of Indebtedness Outsta

Schedule of Indebtedness Outstanding (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 28, 2019
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 1,336,662	$ 1,039,162
Debt Issuance Costs, Noncurrent, Net	644	780
Long-term Debt	1,336,018	1,038,382
Line of Credit
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 600,000	600,000
Debt Instrument, Maturity Date	May 5, 2024
Senior Notes - Series 2020-A due March 11, 2030
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 300,000	0
Debt Instrument, Maturity Date	Mar. 11, 2030
Senior Notes - Series 2015 A due February 15, 2022
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 225,000	225,000
Debt Instrument, Maturity Date	Feb. 15, 2022
Senior Notes - Series 2015-B due February 14, 2025
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 200,000	200,000
Debt Instrument, Maturity Date	Feb. 14, 2025
Other
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 11,662	$ 14,162

Indebtedness (Narrative) (Detai

Indebtedness (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Dec. 28, 2019
Debt Instrument [Line Items]
Line of Credit Facility, Interest Rate at Period End	0.95%
General Discussion of Derivative Instruments and Hedging Activities	We are exposed to market risk from fluctuations in the variable interest rates on outstanding indebtedness under our Credit Agreement. In order to manage this exposure, we have entered into an interest rate swap agreement to hedge the variability of cash flows associated with such interest obligations. The interest rate swap is designated as a cash flow hedge, which effectively fixes the interest rate on the hedged indebtedness under our Credit Agreement at 3.06%
Derivative, Fair Value, Net	$ 41	$ 17
Debt Instrument, Amount Uncommitted and Available for Sale	1,500
Senior Notes - Series 2020-A due March 11, 2030
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 300
Debt Instrument, Interest Rate, Stated Percentage	2.50%
Debt Instrument, Maturity Date	Mar. 11, 2030
Debt Instrument, Frequency of Periodic Payment	payable semiannually
Debt Instrument, Date of First Required Payment	Sep. 11, 2020
Debt Instrument, Restrictive Covenants	The Series 2020-A Notes are subject to the terms of the 2019 Shelf Agreement, which contains customary events of default and covenants related to limitations on indebtedness and transactions with affiliates and the maintenance of certain financial ratios.

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Dec. 28, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements, Valuation Processes, Description	We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. We estimate the fair value of our long-term, variable rate debt using a Level 3 discounted cash flow analysis based on LIBOR rate forward curves.
Fair value of long-term debt, including current maturities	$ 1,340	$ 1,070
Unsecured Long-term Debt, Noncurrent	$ 1,330	$ 1,030

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value, Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 28, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	$ 644,311	$ 431,981
Level 1 [Member] | Money market funds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	56,855	185,666
Level 2 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	19,676	64,286
Level 2 [Member] | Commercial paper [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	1,600
Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	1,150
Level 3 [Member] | Money market funds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Level 3 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Short-term investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	473,323	85,819
Short-term investments [Member] | Level 2 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	21,248	2,506
Short-term investments [Member] | Level 2 [Member] | Commercial paper [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	259,015
Short-term investments [Member] | Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	193,060	83,313
Short-term investments [Member] | Level 3 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Short-term investments [Member] | Level 3 [Member] | Commercial paper [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0
Short-term investments [Member] | Level 3 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Long-term investments [Member] | Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	91,707	96,210
Long-term investments [Member] | Level 3 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	$ 0	$ 0

Gain on Sale of Businesses (Det

Gain on Sale of Businesses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019	Sep. 30, 2020	Sep. 28, 2019	Jul. 01, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale of businesses			$ 229,471	$ 0
Gain on sale of businesses	$ 216,869	$ 0	$ 216,869	$ 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | CompuGroup Medical SE & Co. KGaA [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net					$ 7,334
Disposal Group, Including Discontinued Operation, Inventory, Current					65
Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current					5,759
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current					336
Disposal Group, Including Discontinued Operation, Right-of-Use Asset					554
Disposal Group, Including Discontinued Operation, Capitalized Computer Software, Net					5,532
Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent					7,692
Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent					3,687
Disposal Group, Including Discontinued Operation, Accounts Payable, Current					(1,631)
Disposal Group, Including Discontinued Operation, Deferred Revenue, Noncurrent					(16,655)
Disposal Group, Including Discontinued Operation, Employee-related Liabilities, Current					(4,545)
Disposal Group, Including Discontinued Operation, Other Liabilities, Current					(511)
Disposal Group, Including Discontinued Operation, Consideration					226,623
Disposal Group, Including Discontinue Operation, Net Assets/(Liabilities)					(7,617)
VAT and other transaction taxes, net	(2,142)
Sale of businesses	224,481
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | CompuGroup Medical SE & Co. KGaA [Member] | Gain on sale of businesses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration					226,623
Disposal Group, Including Discontinue Operation, Net Assets/(Liabilities)					$ (7,617)
Transaction Expenses	(5,573)
Foreign Currency Adjustment	1,263
Gain on sale of businesses	214,696
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | R1 RCM Inc. [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of businesses	$ 2,000

Gain on Sale of Businesses (Nar

Gain on Sale of Businesses (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019	Sep. 30, 2020	Sep. 28, 2019	Jul. 01, 2020
Discontinued Operations and Disposal Groups [Abstract]
Gain on sale of businesses	$ 216,869	$ 0	$ 216,869	$ 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | CompuGroup Medical SE & Co. KGaA [Member]
Discontinued Operations and Disposal Groups [Abstract]
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal	On July 1, 2020, we sold certain of our business operations, primarily conducted in Germany and Spain, to affiliates of CompuGroup Medical SE & Co. KGaA ("CGM"), as a part of our portfolio management strategy. Such operations included the associates, intellectual property, client contracts, other assets, and liabilities related to our medico®, Selene®, Soarian Health Archive®, and Soarian® Integrated Care solution offerings.
Disposal Group, Including Discontinued Operation, Consideration					$ 226,623
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal	On July 1, 2020, we sold certain of our business operations, primarily conducted in Germany and Spain, to affiliates of CompuGroup Medical SE & Co. KGaA ("CGM"), as a part of our portfolio management strategy. Such operations included the associates, intellectual property, client contracts, other assets, and liabilities related to our medico®, Selene®, Soarian Health Archive®, and Soarian® Integrated Care solution offerings.
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | R1 RCM Inc. [Member]
Discontinued Operations and Disposal Groups [Abstract]
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal	On August 3, 2020, we sold certain of our revenue cycle outsourcing business operations to affiliates of R1 RCM Inc., as a part of our portfolio management strategy. Such operations included the associates, client contracts, certain other assets, and certain liabilities related to our commercial revenue cycle outsourcing services business.
Gain on sale of businesses	$ 2,000
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal	On August 3, 2020, we sold certain of our revenue cycle outsourcing business operations to affiliates of R1 RCM Inc., as a part of our portfolio management strategy. Such operations included the associates, client contracts, certain other assets, and certain liabilities related to our commercial revenue cycle outsourcing services business.

Income Taxes (Details)

Income Taxes (Details)	9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019
Income Tax Disclosure [Abstract]
Effective tax rate	21.70%	18.90%

Earnings Per Share (Reconciliat

Earnings Per Share (Reconciliation Of The Numerators And The Denominators Of The Basic And Diluted Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019	Sep. 30, 2020	Sep. 28, 2019
Earnings Per Share [Abstract]
Income available to common shareholders, basic	$ 356,676	$ 81,935	$ 638,583	$ 375,123
Income available to common shareholders including assumed conversions, diluted	$ 356,676	$ 81,935	$ 638,583	$ 375,123
Basic weighted average shares outstanding	305,759	315,876	306,759	320,282
Stock options and non-vested shares, incremental shares	2,607	3,237	2,365	3,079
Diluted weighted average shares outstanding	308,366	319,113	309,124	323,361
Basic earnings per share	$ 1.17	$ 0.26	$ 2.08	$ 1.17
Diluted earnings per share	$ 1.16	$ 0.26	$ 2.07	$ 1.16

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - $ / shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019	Sep. 30, 2020	Sep. 28, 2019
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, amount	3.9	7.7	4.4	10.1
Antidilutive securities excluded from computation of earnings per share, exercise price, lower range limit	$ 55.24	$ 54.87	$ 52.32	$ 51.87
Antidilutive securities excluded from computation of earnings per share, exercise price, upper range limit	$ 76.49	$ 75.83	$ 76.49	$ 75.83

Share-Based Compensation (Sched

Share-Based Compensation (Schedule Of Stock Options Activity) (Details) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares
Share-based Payment Arrangement [Abstract]
Outstanding at beginning of year, number of shares | shares	15,416
Outstanding at beginning of year, weighted-average exercise price | $ / shares	$ 56.36
Granted, number of shares | shares	3
Granted, weighted-average exercise price | $ / shares	$ 72.36
Exercised, number of shares | shares	(4,009)
Exercised, weighted-average exercise price | $ / shares	$ 50.67
Forfeited and expired, number of shares | shares	(228)
Forfeited and expired, weighted-average exercise price | $ / shares	$ 61.32
Outstanding end of year, number of shares | shares	11,182
Outstanding at end of year, weighted-average exercise price | $ / shares	$ 58.31
Outstanding at end of year, aggregate intrinsic value | $	$ 156,372
Outstanding at end of year, weighted-average remaining contractual term	5 years 8 months 12 days
Exercisable at end of year, number of shares | shares	7,248
Exercisable at end of year, weighted-average exercise price | $ / shares	$ 56.87
Exercisable at end of year, aggregate intrinsic value | $	$ 111,738
Exercisable at end of year, weighted-average remaining contractual term	4 years 10 months 6 days

Share-Based Compensation (Sch_2

Share-Based Compensation (Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions) (Details)	9 Months Ended
	Sep. 30, 2020$ / shares
Share-based Payment Arrangement [Abstract]
Expected volatility (%)	24.50%
Expected dividend rate	1.00%
Expected term (yrs)	6 years
Risk-free rate (%)	1.10%
Fair value per option	$ 16.64

Share-Based Compensation (Sch_3

Share-Based Compensation (Schedule Of Non-Vested Shares Activity) (Details) - Restricted Stock [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of year, number of shares | shares	2,634
Outstanding at beginning of year, weighted-average grant date fair value | $ / shares	$ 65.30
Granted, number of shares | shares	2,520
Granted, weighted-average grant date fair value | $ / shares	$ 69.99
Vested, number of shares | shares	(946)
Vested, weighted-average grant date fair value | $ / shares	$ 66.30
Forfeited, number of shares | shares	(97)
Forfeited, weighted-average grant date fair value | $ / shares	$ 67.24
Outstanding at end of year, number of shares | shares	4,111
Outstanding at end of year, weighted-average grant date fair value | $ / shares	$ 67.90

Share-Based Compensation (Compe

Share-Based Compensation (Compensation Expense Recognized In The Condensed Consolidated Statements Of Operations) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019	Sep. 30, 2020	Sep. 28, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amounts charged against earnings, before income tax benefit	$ 38,137	$ 31,782	$ 111,724	$ 78,103
Amount of related income tax benefit recognized in earnings	7,818	6,330	22,452	14,888
Stock option and non-vested share compensation expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amounts charged against earnings, before income tax benefit	37,920	30,537	110,500	73,421
Associate stock purchase plan expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amounts charged against earnings, before income tax benefit	1,367	1,321	4,195	4,612
Amounts capitalized in software development costs, net of amortization
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amounts charged against earnings, before income tax benefit	$ (1,150)	$ (76)	$ (2,971)	$ 70

Schedule of Accumulated Other C

Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 28, 2019	Jun. 29, 2019	Mar. 30, 2019	Dec. 28, 2019	Dec. 29, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net	$ (138,015)	$ (149,671)	$ (159,363)	$ (128,550)	$ (112,848)	$ (100,594)	$ (118,660)	$ (103,552)
OCI, before Reclassifications, Net of Tax, Attributable to Parent	9,102	7,494	(41,825)	(15,797)	(12,107)	2,958
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	2,554	2,198	1,122	95	(147)	0
Accumulated Foreign Currency Adjustment Attributable to Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net	(108,085)	(117,696)	(126,893)	(112,397)	(100,718)	(100,618)	(106,347)	(102,939)
OCI, before Reclassifications, Net of Tax, Attributable to Parent	9,611	9,197	(20,546)	(11,679)	(100)	2,321
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	0	0	0	0	0	0
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net	(30,628)	(32,893)	(31,886)	(16,407)	(12,370)	0	(12,578)	0
OCI, before Reclassifications, Net of Tax, Attributable to Parent	(289)	(3,205)	(20,430)	(4,135)	(12,223)	0
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	2,554	2,198	1,122	98	(147)	0
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net	698	918	(584)	254	240	24	$ 265	$ (613)
OCI, before Reclassifications, Net of Tax, Attributable to Parent	(220)	1,502	(849)	17	216	637
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	$ 0	$ 0	$ 0	$ (3)	$ 0	$ 0

Reclassification out of Accumul

Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019	Sep. 30, 2020	Sep. 28, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income, net	$ 48,020	$ 13,535	$ 78,247	$ 44,973
Income Tax Expense (Benefit)	(103,164)	(20,377)	(176,758)	(87,688)
Net earnings	356,676	81,935	638,583	375,123
Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net earnings	(2,554)	(95)	(5,874)	52
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income, net	(3,213)	(122)	(7,383)	58
Income Tax Expense (Benefit)	659	24	1,509	(9)
Net earnings	(2,554)	(98)	(5,874)	49
Reclassification out of Accumulated Other Comprehensive Income | AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income, net	0	4	0	4
Income Tax Expense (Benefit)	0	1	0	1
Net earnings	$ 0	$ 3	$ 0	$ 3

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options	$ 223			$ 223
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	58			58
Stock Repurchase Program, Authorized Amount	3,700			3,700
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 1,030			$ 1,030
Dividends Payable, Date Declared	Sep. 10, 2020	May 21, 2020	Mar. 19, 2020
Dividends Payable, Amount Per Share	$ 0.18	$ 0.18	$ 0.18	$ 0.18
Dividends Payable, Date to be Paid	Oct. 13, 2020	Jul. 17, 2020	Apr. 17, 2020
Dividends Payable, Date of Record	Sep. 25, 2020	Jun. 5, 2020	Apr. 3, 2020
Dividends Payable	$ 56			$ 56
Treasury stock purchases				$ 650
Treasury Stock, Shares, Acquired				9,200
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of recognition for remaining share-based compensation expense				2 years 1 month 13 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of recognition for remaining share-based compensation expense				1 year 11 months 15 days

Contingencies Contingencies (De

Contingencies Contingencies (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Dec. 29, 2018	Sep. 30, 2020
Fujitsu [Member]
Commitments and Contingencies Disclosure [Abstract]
Loss Contingency, Management's Assessment and Process		As previously disclosed, we continue to be in dispute with Fujitsu Services Limited ("Fujitsu") regarding Fujitsu's obligation to pay amounts to us due upon the termination of a subcontract, including client receivables, in connection with Fujitsu's contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England. The NHS terminated its contract with Fujitsu, which gave rise to the termination of our subcontract with Fujitsu. We filed a request for arbitration with the London Court of International Arbitration on April 22, 2019 seeking damages. On December 30, 2019, Fujitsu filed its Defense and Counterclaim (the "Counterclaim") in response. In its Counterclaim, Fujitsu defends against our claim in full and argues that we are liable to Fujitsu for: (i) £306 million in damages based on our alleged fraudulent misrepresentations inducing Fujitsu to enter into the subcontract; or (ii) alternatively, £173.8 million in damages based on our alleged breaches of the subcontract.
Loss Contingencies [Line Items]
Loss Contingency, Management's Assessment and Process		As previously disclosed, we continue to be in dispute with Fujitsu Services Limited ("Fujitsu") regarding Fujitsu's obligation to pay amounts to us due upon the termination of a subcontract, including client receivables, in connection with Fujitsu's contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England. The NHS terminated its contract with Fujitsu, which gave rise to the termination of our subcontract with Fujitsu. We filed a request for arbitration with the London Court of International Arbitration on April 22, 2019 seeking damages. On December 30, 2019, Fujitsu filed its Defense and Counterclaim (the "Counterclaim") in response. In its Counterclaim, Fujitsu defends against our claim in full and argues that we are liable to Fujitsu for: (i) £306 million in damages based on our alleged fraudulent misrepresentations inducing Fujitsu to enter into the subcontract; or (ii) alternatively, £173.8 million in damages based on our alleged breaches of the subcontract.
Loss Contingency Accrual, Provision	$ 45
NextGen [Member]
Commitments and Contingencies Disclosure [Abstract]
Loss Contingency, Management's Assessment and Process		Cerner Health Services, Inc. ("Cerner HS"), a wholly owned subsidiary of Cerner Corporation, filed a lawsuit in the Chester County, Pennsylvania, Court of Common Pleas against NextGen Healthcare Information Systems, LLC ("NextGen") relating to a dispute arising out of a supplier relationship initially established between Siemens Health Services, Inc. ("Health Services") and NextGen prior to the acquisition of the assets of Health Services by Cerner HS in 2015. In September 2017, the court issued a preliminary injunction to prevent NextGen from refusing to honor certain contractual obligations to support Cerner HS's clients who use NextGen ambulatory EHR solutions. In September 2018, NextGen filed a counterclaim alleging breach of contract and tortious interference but did not specify its damages. In August 2019, NextGen provided an expert report alleging profit disgorgement damages of $135 million or, alternatively, $30.5 million in lost profit damages, but the report did not discuss how our actions allegedly caused NextGen's damages. In December 2019, we deposed NextGen's expert, gaining additional clarity on categories of alleged damages but not on the alleged theories of liability. A jury trial is set to begin on January 25, 2021. We believe NextGen's claims are without merit and will vigorously defend against them; however, there can be no assurances as to the outcome of the dispute. We have not concluded that a loss related to the claims raised by NextGen in its counterclaim is probable, nor have we accrued a liability related to these claims. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by NextGen's expert, and the continued lack of clarity on the causal connection between Cerner Corporation's and Cerner HS's actions and any alleged damages.
Loss Contingencies [Line Items]
Loss Contingency, Management's Assessment and Process		Cerner Health Services, Inc. ("Cerner HS"), a wholly owned subsidiary of Cerner Corporation, filed a lawsuit in the Chester County, Pennsylvania, Court of Common Pleas against NextGen Healthcare Information Systems, LLC ("NextGen") relating to a dispute arising out of a supplier relationship initially established between Siemens Health Services, Inc. ("Health Services") and NextGen prior to the acquisition of the assets of Health Services by Cerner HS in 2015. In September 2017, the court issued a preliminary injunction to prevent NextGen from refusing to honor certain contractual obligations to support Cerner HS's clients who use NextGen ambulatory EHR solutions. In September 2018, NextGen filed a counterclaim alleging breach of contract and tortious interference but did not specify its damages. In August 2019, NextGen provided an expert report alleging profit disgorgement damages of $135 million or, alternatively, $30.5 million in lost profit damages, but the report did not discuss how our actions allegedly caused NextGen's damages. In December 2019, we deposed NextGen's expert, gaining additional clarity on categories of alleged damages but not on the alleged theories of liability. A jury trial is set to begin on January 25, 2021. We believe NextGen's claims are without merit and will vigorously defend against them; however, there can be no assurances as to the outcome of the dispute. We have not concluded that a loss related to the claims raised by NextGen in its counterclaim is probable, nor have we accrued a liability related to these claims. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by NextGen's expert, and the continued lack of clarity on the causal connection between Cerner Corporation's and Cerner HS's actions and any alleged damages.

Segment Reporting (Summary Of T

Segment Reporting (Summary Of The Operating Information) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 28, 2019	Sep. 30, 2020	Sep. 28, 2019
Segment Reporting Information [Line Items]
Revenues	$ 1,368,673	$ 1,429,428	$ 4,110,763	$ 4,250,366
Costs of revenue	231,889	271,778	698,268	793,655
Operating expenses	941,833	1,068,873	2,892,270	3,038,873
Total costs and expenses	1,173,722	1,340,651	3,590,538	3,832,528
Gain on sale of businesses	216,869	0	216,869	0
Operating earnings (loss)	411,820	88,777	737,094	417,838
Domestic Segment
Segment Reporting Information [Line Items]
Revenues	1,230,769	1,265,263	3,645,397	3,762,205
Costs of revenue	219,938	246,634	638,284	719,119
Operating expenses	566,777	639,590	1,724,545	1,817,244
Total costs and expenses	786,715	886,224	2,362,829	2,536,363
Gain on sale of businesses	0		0
Operating earnings (loss)	444,054	379,039	1,282,568	1,225,842
International Segment [Member]
Segment Reporting Information [Line Items]
Revenues	137,904	164,165	465,366	488,161
Costs of revenue	11,951	25,144	59,984	74,536
Operating expenses	58,626	68,153	182,594	209,580
Total costs and expenses	70,577	93,297	242,578	284,116
Gain on sale of businesses	0		0
Operating earnings (loss)	67,327	70,868	222,788	204,045
Other
Segment Reporting Information [Line Items]
Operating expenses	316,430	361,130	985,131	1,012,049
Total costs and expenses	316,430	361,130	985,131	1,012,049
Gain on sale of businesses	216,869		216,869
Operating earnings (loss)	$ (99,561)	$ (361,130)	$ (768,262)	$ (1,012,049)